STAT+: Novartis data set up multibillion-dollar battle over breast cancer drugs
Novartis announced data Monday that could set up one of the biggest marketing battles in cancer.
At issue is the market for medicines called CDK 4/6 inhibitors. The first of these drugs, Pfizer’s Ibrance, is a $5-billion-a-year product and one of that company’s top sellers. But it has been losing market share to Eli Lilly’s Verzenio.
